Business Context and Reporting Period
Company: AmerisourceBergen Corporation (now Cencora, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: September 30, 2003
Business Overview: The Company is a leading wholesale distributor of pharmaceutical products and related healthcare services in the United States. Operations are organized into two reportable segments: Pharmaceutical Distribution (wholesale distribution to hospitals, retail pharmacies, and specialty providers) and PharMerica (institutional pharmacy services for long-term care and workers' compensation). The Company was formed via the merger of AmeriSource Health Corporation and Bergen Brunswig Corporation in August 2001.
Key Financial Metrics (Fiscal Year 2003)
| Metric | 2003 (in millions) | 2002 (in millions) |
|---|---|---|
| Operating Revenue | $45,537 | $40,241 |
| Total Revenue (incl. bulk deliveries) | $49,657 | $45,235 |
| Gross Profit | $2,247 | $2,024 |
| Operating Income | $883 | $718 |
| Net Income | $441 | $345 |
| Diluted EPS | $3.89 | $3.16 |
| Cash and Cash Equivalents | $800 | $663 |
| Total Debt (incl. current portion) | $1,784 | $1,817 |
| Stockholders' Equity | $4,005 | $3,316 |
Margins: Gross profit margin was 4.93% of operating revenue (down from 5.03% in 2002). Operating income margin was 1.94% (up from 1.79%).
Material Changes vs. Prior Period
- Revenue Growth: Operating revenue increased 13% to $45.5 billion, driven primarily by the Pharmaceutical Distribution segment (+13%). Bulk deliveries decreased 17% due to the conversion of bulk business to warehouse-serviced business.
- Profitability: Net income rose 28% to $441 million. Operating income increased 23% to $883 million, aided by a reduction in special items (facility consolidations and merger costs) from $24.2 million in 2002 to $8.9 million in 2003.
- Segment Performance:
- Pharmaceutical Distribution: Operating income grew 20% to $788 million. Gross margin declined slightly (3.85% vs 3.87%) due to competitive pricing and customer mix shifts, offset by operational efficiencies.
- PharMerica: Operating income grew 24% to $104 million. Revenue grew 9%, driven by the workers' compensation business, though growth slowed in the second half due to the loss of a significant customer.
- Acquisitions: The Company completed several strategic acquisitions in fiscal 2003, including US Bioservices ($160M), Anderson Packaging ($100M), and Bridge Medical ($28M), expanding specialty and packaging capabilities.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management expects industry growth rates of 10-13% over the next four years. The PharMerica segment revenue growth is expected to be in the mid-single digits for fiscal 2004 due to a slowdown in the workers' compensation business.
- Capital Allocation: The Company plans to spend approximately $150 million to $200 million on capital expenditures in fiscal 2004, primarily for the "Optimiz" program to consolidate distribution facilities from 51 to 30.
- Key Risks:
- Customer Concentration: Sales to the federal government (primarily the VA) represented 9% of revenue. The VA contract expires in early 2004, and the Company is awaiting a decision on renewal.
- Margin Pressure: Intense competition and manufacturer efforts to control the supply chain (limiting secondary source purchasing) may erode gross margins.
- Regulatory: Changes in Medicare/Medicaid reimbursement and new legislation regarding prescription drug benefits (effective 2006) pose uncertainty.
- Unusual Items: A $4.2 million loss was recorded on the early retirement of debt. Special items (severance and facility consolidation) reduced operating income by $8.9 million.
Investor Verification Checklist
- VA Contract Status: Verify the outcome of the U.S. Department of Veterans Affairs contract renewal, which represents approximately 80% of federal government sales.
- Margin Trends: Monitor gross profit margins in the Pharmaceutical Distribution segment for continued pressure from competitive pricing and manufacturer supply chain restrictions.
- Integration Costs: Track the realization of synergies from the "Optimiz" facility consolidation program and associated capital expenditures.
- Acquisition Integration: Assess the performance of recent acquisitions (US Bioservices, Anderson Packaging, Bridge Medical) against projected earnings targets.
- Regulatory Impact: Evaluate the potential financial impact of the 2003 federal legislation granting Medicare beneficiaries a prescription drug benefit starting in 2006.